Patient characteristics
A total of 110 patients were enrolled in this study. The median ages of
the 110 patients and donors were 5.5 years (range 0.8-16.7 years) and
26.5 years (range 1-46 years), respectively. Fifty-seven patients
received myeloablative conditioning (busulfan plus cyclophosphamide,
total-body irradiation plus cyclophosphamide, or total-body irradiation
plus cyclophosphamide and etoposide), and 53 patients received
nonmyeloablative conditioning (fludarabine plus cyclophosphamide). All
patients received PBSCT. Ninety-eight of the 110 patients were treated
with antithymocyte globulin (ATG) during conditioning, and 61 patients
were offered corticosteroid therapy (Table 1).